CDT says new patent-protected solid forms of drug compounds improve stability, solubility, manufacturability

• CDT Equity reported new solid forms of existing drug compounds with improved stability, solubility, manufacturability versus prior forms.
• Patent protection tied to its Substance of Matter portfolio, aiming to extend commercial life through new formulations for specific patient needs.
• Sarborg Signature Intelligence work identified potential new uses, including combinations with marketed drugs; patents filed covering these findings.
• Next steps include validation in lab models to support partnering talks, targeting underserved diseases with limited treatment options.
• Strategy centers on AI-driven data, experimental evidence, 20-year patents to de-risk assets and improve out-licensing appeal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280500PRIMZONEFULLFEED9817569) on August 28, 2026, and is solely responsible for the information contained therein.